In a phase I/II clinical trial, the authors reported that anakinra (an IL-1 receptor antagonist) therapy in corticosteroid-resistant autoimmune inner ear disease patients was effective in a small cohort of patients and that plasma IL-1β level was associated with both clinical hearing response and disease relapse [24]. The gene discussed is IL1B; the disease is autoimmune inner ear disease.